Developer docs
API playgroundTry for free, no card

Search company profiles

Alembic Pharmaceuticals

Full company profile

uuid0004bkm

Namestring
Alembic Pharmaceuticals
Legal namestring
Alembic Pharmaceuticals Limited
Company typeenum
Public
Founded yearint
1907
Descriptiontext

Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical manufacturer founded in 1907 and headquartered in Vadodara, Gujarat, publicly listed on the NSE and BSE. The company operates across three business segments — India Formulations (domestic specialty medicines across 10+ therapy areas), International Generics (US front-end operations plus distribution into 75+ countries including Europe, Canada, Australia, Brazil, and South Africa), and Active Pharmaceutical Ingredients (in-house API development and supply). It runs 9 manufacturing facilities in India, employs 17,000+ people, and has accumulated 243+ ANDA approvals from the USFDA plus 132 Drug Master File filings.

The company's product portfolio is heavily weighted toward generic pharmaceuticals (therapeutic categories include oncology, cardiovascular, CNS, anti-infectives, diabetes, dermatology, and gastrointestinal), with a recently launched branded specialty franchise anchored by Pivya (pivmecillinam), the first new antibiotic approved for uncomplicated urinary tract infections in roughly two decades, acquired via the $12 million Utility Therapeutics deal and commercialized through wholly owned subsidiary Alembic Therapeutics LLC. Revenue mechanics rely on one-time sales through institutional and pharmacy distribution channels rather than subscription or licensing models; pricing is not publicly disclosed. The US business accounts for approximately 30% of consolidated revenue and is targeted for 10-15% growth in FY27. FY26 consolidated revenue from operations was ₹7,344.9 crore with consolidated net profit of ₹6,638.61 crore, against a Q4 FY26 EBITDA margin of 12.3% that management expects to recover to 20% over 2-3 years. Other subsidiaries include Aleor Dermaceutical Limited (joint venture with Orbicular, dermatology focus) and a 45% Canadian joint venture acquired in June 2026.

Short descriptiontext

Alembic Pharmaceuticals is a vertically integrated Indian pharmaceutical manufacturer operating India Formulations, International Generics (US-anchored), and API businesses across 75+ countries with 243+ USFDA ANDA approvals and 9 manufacturing facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersVadodara, India
HQ citystring
Vadodara
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals manufacturing, active pharmaceutical ingredients, finished dosage formulations, USFDA ANDA approvals, branded specialty drugs
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1US Generics Business
TypeOne Time License
Description

Sales of generic pharmaceutical products in the US market through ANDA approvals. US formulations segment generated ₹564 crore in Q4 FY26 with 11% YoY growth. US business accounts for 30% of total revenue.

business-standard.com
2India Formulations
TypeOne Time License
Description

Domestic Indian market sales through multiple therapy divisions including chronic therapies. Revenue from India branded business growing in-line with industry trends.

cnbctv18.com
3Active Pharmaceutical Ingredients (APIs)
TypeOne Time License
Description

Manufacturing and sale of pharmaceutical ingredients to other pharmaceutical companies globally. Company develops in-house APIs expanding portfolio globally.

alembicpharmaceuticals.com
4US Branded Specialty
TypeOne Time License
Description

Launched branded drug Pivya through Alembic Therapeutics subsidiary after acquiring Utility Therapeutics for $12 million. First branded pharmaceutical product launch in the US market targeting uncomplicated urinary tract infections.

business-standard.com
Cost components7 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alembic Pharmaceuticals manufactures and sells generic pharmaceutical products across therapeutic areas including oncology, cardiovascular, central nervous system, anti-infective, dermatology, diabetes, and gastrointestinal, through three business segments: India Formulations (domestic specialty branded drugs), International Generics (US ANDA-approved generic finished dosage forms and global exports), and Active Pharmaceutical Ingredients (in-house API manufacturing sold to other pharma companies). The company also markets branded specialty drugs in the US through its Alembic Therapeutics LLC subsidiary, with Pivya (pivmecillinam) for uncomplicated urinary tract infections being its first branded product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 11% YoY growth in US formulations business
+2 more records
Product overview1 text field

Alembic Pharmaceuticals is a vertically integrated pharmaceutical company with three core business segments: India Formulations (domestic specialty medicines), International Generics (global generic products with US front-end operations), and Active Pharmaceutical Ingredients (in-house API manufacturing). The company operates 9 manufacturing facilities and has received over 244 ANDA approvals from USFDA. Recent strategic moves include entry into US branded pharmaceuticals through its Alembic Therapeutics subsidiary, launch of Pivya (its first branded antibiotic acquired from Utility Therapeutics), and expansion into dermatology through the Aleor JV. The company's diverse generic portfolio spans therapeutic areas including oncology, cardiovascular, diabetes, anti-infectives, CNS, and dermatology.

Product and service24 records
1India Formulations (Domestic Branded Specialty)
CategoryBranded Pharmaceutical Products (India)
Description

Domestic Indian market sales of branded specialty pharmaceutical products across multiple therapy areas, distributing through the company's India business sales infrastructure. Targeted at medical professionals, hospitals, and patients in India.

2International Generics (US ANDA + Global Exports)
CategoryGeneric Pharmaceutical Products (International)
Description

Global suite of USFDA ANDA-approved generic pharmaceutical products (244+ cumulative approvals) sold through the US front-end and via strategic distribution partnerships across Europe, Canada, Australia, Brazil, and South Africa. Targeted at wholesalers, distributors, pharmacy chains, and healthcare institutions in 75+ countries.

3Active Pharmaceutical Ingredients (APIs)
CategoryPharmaceutical Ingredients / APIs
Description

In-house manufactured pharmaceutical ingredients sold to other pharmaceutical companies globally across therapeutic categories including oncology, cardiovascular, diabetes, and antibiotics, supported by 132 Drug Master File filings.

4Pivya (pivmecillinam) Tablets
CategoryBranded Specialty Pharmaceutical (US)
Description

Branded antibiotic for uncomplicated urinary tract infections (uUTI) in women; first antibiotic in approximately 20 years to receive FDA approval for uUTI. Marketed through Alembic Therapeutics LLC in approximately 30 US territories.

5Levothyroxine Sodium Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic thyroid hormone replacement therapy for hypothyroidism and thyroid cancer management; available in 12 strength variants from 25 mcg to 300 mcg.

6Dapagliflozin Tablets
CategoryGeneric Pharmaceutical Product
Description

SGLT2 inhibitor for controlling blood sugar in adults with type-2 diabetes and reducing hospitalization risk for heart failure; available in 5 mg and 10 mg strengths.

7Oseltamivir Phosphate for Oral Suspension
CategoryGeneric Pharmaceutical Product
Description

Neuraminidase inhibitor oral suspension used to treat acute, uncomplicated influenza A and B in patients aged two weeks and above.

8Fingolimod Capsules, 0.5 mg
CategoryGeneric Pharmaceutical Product
Description

Sphingosine 1-phosphate receptor modulator indicated for treating relapsing forms of multiple sclerosis in patients 10 years and older.

9Binimetinib Tablets, 45 mg
CategoryGeneric Pharmaceutical Product
Description

Kinase inhibitor used in combination with encorafenib for treating unresectable or metastatic melanoma with BRAF mutations and metastatic non-small cell lung cancer.

10Darolutamide Tablets, 300 mg
CategoryGeneric Pharmaceutical Product
Description

Oral androgen receptor inhibitor for treating non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and in combination with docetaxel.

11Tretinoin Cream USP, 0.05%
CategoryGeneric Pharmaceutical Product
Description

Topical cream indicated for the treatment of acne vulgaris.

12Dapsone Gel, 5%
CategoryGeneric Pharmaceutical Product
Description

Topical treatment for acne vulgaris.

13Haloperidol Tablets
CategoryGeneric Pharmaceutical Product
Description

Antipsychotic medication for managing manifestations of psychotic disorders and controlling tics and vocal utterances of Tourette's Disorder; available in five strengths.

14Larotrectinib Capsules
CategoryGeneric Pharmaceutical Product
Description

Kinase inhibitor for treating solid tumors with NTRK gene fusion; available in 25 mg and 100 mg dosages.

15Methotrexate Injection USP
CategoryGeneric Pharmaceutical Product
Description

Injection indicated for neoplastic diseases including leukemia and various cancers, rheumatoid arthritis, and severe psoriasis; available in multi-dose and single-dose vial formulations.

16Lamotrigine Orally Disintegrating Tablets
CategoryGeneric Pharmaceutical Product
Description

Anticonvulsant for adjunctive therapy in partial-onset seizures, generalized seizures of Lennox Gastaut syndrome, and maintenance treatment of bipolar I disorder.

17Efinaconazole Topical Solution, 10%
CategoryGeneric Pharmaceutical Product
Description

Topical antifungal solution for treating onychomycosis of the toenails.

18Carbidopa, Levodopa and Entacapone Tablets
CategoryGeneric Pharmaceutical Product
Description

Combination medication for the treatment of Parkinson's disease; available in six dosage strengths.

19Dasatinib Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic kinase inhibitor for treating Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).

20Sumatriptan Injection USP Autoinjector
CategoryGeneric Pharmaceutical Product (Drug-Device Combination)
Description

Drug-device combination product for migraine and cluster headache treatment; available in 4 mg/0.5 ml and 6 mg/0.5 ml single-dose autoinjector systems.

21Dexlansoprazole Delayed-Release Capsules
CategoryGeneric Pharmaceutical Product
Description

Generic proton pump inhibitor for treating gastroesophageal reflux disease (GERD).

22Cyclophosphamide Capsules
CategoryGeneric Pharmaceutical Product
Description

Indicated for treatment of malignant diseases and minimal change nephrotic syndrome in pediatric patients; available in 25 mg and 50 mg dosages.

23Bosutinib Tablets, 400 mg
CategoryGeneric Pharmaceutical Product
Description

Kinase inhibitor used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML).

24Macitentan Tablets, 10 mg
CategoryGeneric Pharmaceutical Product
Description

Endothelin receptor antagonist for treating pulmonary arterial hypertension.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Canadian Joint Venture
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-06
Description

Alembic Pharmaceuticals announced acquiring a 45% stake in a Canadian joint venture as part of its strategy to strengthen its global pharmaceutical footprint.

cnbctv18.com
2Alembic Lifesciences Philippines Inc.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

New subsidiary incorporated in the Philippines with parent company holding 99.99% stake. Authorized share capital of 12 million Philippine pesos. Will focus on exploring business opportunities and distributing pharmaceutical products in the region.

business-standard.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Strategic partnership to deploy an AI-powered learning and skilling platform for 9,000+ employees across different regions. The platform addresses compliance, GMP, pharmacovigilance, and regulatory documentation needs specific to regulated pharmaceutical environments, marking Alembic's transition from previous Success Factor LMS system.

4Utility Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-03
Description

Alembic acquired Utility Therapeutics for approximately $12 million in 2024-25, gaining exclusive commercial rights to Pivya (pivmecillinam) antibiotic for the US market. Pivya was the first antibiotic in about 20 years to gain FDA approval for uncomplicated urinary tract infections.

ainvest.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Sun Pharmaceutical Industries
TypeDirect peer
Description

India's largest pharmaceutical company and the most direct comparator to Alembic, with a similarly diversified US generics business, large India branded formulations franchise, and vertically integrated API manufacturing. Both companies target the same USFDA approval pipeline and compete head-to-head on ANDA molecules.

TypeDirect peer
Description

Major Indian generic and branded pharmaceutical manufacturer with a strong US generics presence, India branded business, and API capabilities. Directly comparable to Alembic in scale, geographic mix, and therapeutic area focus.

TypeDirect peer
Description

Vertically integrated Indian pharmaceutical company with global generics, biosimilars, and API operations. Comparable to Alembic in business model, US generics focus, and integrated API-to-finished-dose manufacturing footprint.

TypeDirect peer
Description

One of India's largest generic manufacturers with a substantial US generics franchise built on ANDA approvals. Competes directly with Alembic for USFDA approvals on complex molecules including injectables and oncology.

TypeDirect peer
Description

Indian pharmaceutical company with a leading US generics business, strong pipeline of complex generics, and India branded formulations. Directly comparable to Alembic in regulatory execution and therapeutic coverage.

TypeDirect peer
Description

Indian pharmaceutical major with a sizable US generics business, India formulations, and API manufacturing. Comparable to Alembic in business mix and pursuit of complex generics and biosimilars.

TypeDirect peer
Description

India-headquartered pharma company with US generics, India branded, and API businesses, pursuing complex generics and specialty therapeutics. Closely comparable to Alembic in scale and strategic positioning.

TypeBroad incumbent
Description

World's largest generic drug manufacturer with a dominant US generics portfolio, broad specialty franchise, and global API operations. While much larger and more diversified, Teva sets the competitive benchmark Alembic faces on every major ANDA molecule.

9Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics leader spun out of Novartis with a leading US generics franchise and broad European presence. Operates as a broad incumbent that competes with Alembic across multiple therapeutic areas and geographies.

TypeDirect peer
Description

Indian pharmaceutical company with US generics, India branded formulations, and API manufacturing. Comparable to Alembic in size, vertical integration, and therapeutic mix including cardiovascular and CNS focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alembic Pharmaceuticals

Generic Pharmaceuticals Manufacturingalembicpharmaceuticals.com

Alembic Pharmaceuticals is a vertically integrated Indian pharmaceutical manufacturer operating India Formulations, International Generics (US-anchored), and API businesses across 75+ countries with 243+ USFDA ANDA approvals and 9 manufacturing facilities.

What Alembic Pharmaceuticals does

Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical manufacturer founded in 1907 and headquartered in Vadodara, Gujarat, publicly listed on the NSE and BSE. The company operates across three business segments — India Formulations (domestic specialty medicines across 10+ therapy areas), International Generics (US front-end operations plus distribution into 75+ countries including Europe, Canada, Australia, Brazil, and South Africa), and Active Pharmaceutical Ingredients (in-house API development and supply). It runs 9 manufacturing facilities in India, employs 17,000+ people, and has accumulated 243+ ANDA approvals from the USFDA plus 132 Drug Master File filings.

The company's product portfolio is heavily weighted toward generic pharmaceuticals (therapeutic categories include oncology, cardiovascular, CNS, anti-infectives, diabetes, dermatology, and gastrointestinal), with a recently launched branded specialty franchise anchored by Pivya (pivmecillinam), the first new antibiotic approved for uncomplicated urinary tract infections in roughly two decades, acquired via the $12 million Utility Therapeutics deal and commercialized through wholly owned subsidiary Alembic Therapeutics LLC. Revenue mechanics rely on one-time sales through institutional and pharmacy distribution channels rather than subscription or licensing models; pricing is not publicly disclosed. The US business accounts for approximately 30% of consolidated revenue and is targeted for 10-15% growth in FY27. FY26 consolidated revenue from operations was ₹7,344.9 crore with consolidated net profit of ₹6,638.61 crore, against a Q4 FY26 EBITDA margin of 12.3% that management expects to recover to 20% over 2-3 years. Other subsidiaries include Aleor Dermaceutical Limited (joint venture with Orbicular, dermatology focus) and a 45% Canadian joint venture acquired in June 2026.

Alembic Pharmaceuticals firmographics

Firmographics
Name
Alembic Pharmaceuticals
Legal name
Alembic Pharmaceuticals Limited
Website
https://alembicpharmaceuticals.com
Company type
Public
Founded year
1907
Operating status
Operating
Headcount range
10,001+ employees
Short description
Alembic Pharmaceuticals is a vertically integrated Indian pharmaceutical manufacturer operating India Formulations, International Generics (US-anchored), and API businesses across 75+ countries with 243+ USFDA ANDA approvals and 9 manufacturing facilities.
Ownership category
akta.pro rank

Alembic Pharmaceuticals industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Generic pharmaceuticals manufacturing
  • Active pharmaceutical ingredients
  • Finished dosage formulations
  • USFDA ANDA approvals
  • Branded specialty drugs

Where Alembic Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Vadodara
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Alembic Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. US Generics Business: Sales of generic pharmaceutical products in the US market through ANDA approvals. US formulations segment generated ₹564 crore in Q4 FY26 with 11% YoY growth. US business accounts for 30% of total revenue.
  2. India Formulations: Domestic Indian market sales through multiple therapy divisions including chronic therapies. Revenue from India branded business growing in-line with industry trends.
  3. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of pharmaceutical ingredients to other pharmaceutical companies globally. Company develops in-house APIs expanding portfolio globally.
  4. US Branded Specialty: Launched branded drug Pivya through Alembic Therapeutics subsidiary after acquiring Utility Therapeutics for $12 million. First branded pharmaceutical product launch in the US market targeting uncomplicated urinary tract infections.

Go-to-market motion2 records

Alembic Pharmaceuticals product offering

Product offering

Core offering

Alembic Pharmaceuticals manufactures and sells generic pharmaceutical products across therapeutic areas including oncology, cardiovascular, central nervous system, anti-infective, dermatology, diabetes, and gastrointestinal, through three business segments: India Formulations (domestic specialty branded drugs), International Generics (US ANDA-approved generic finished dosage forms and global exports), and Active Pharmaceutical Ingredients (in-house API manufacturing sold to other pharma companies). The company also markets branded specialty drugs in the US through its Alembic Therapeutics LLC subsidiary, with Pivya (pivmecillinam) for uncomplicated urinary tract infections being its first branded product.

Product overview

Alembic Pharmaceuticals is a vertically integrated pharmaceutical company with three core business segments: India Formulations (domestic specialty medicines), International Generics (global generic products with US front-end operations), and Active Pharmaceutical Ingredients (in-house API manufacturing). The company operates 9 manufacturing facilities and has received over 244 ANDA approvals from USFDA. Recent strategic moves include entry into US branded pharmaceuticals through its Alembic Therapeutics subsidiary, launch of Pivya (its first branded antibiotic acquired from Utility Therapeutics), and expansion into dermatology through the Aleor JV. The company's diverse generic portfolio spans therapeutic areas including oncology, cardiovascular, diabetes, anti-infectives, CNS, and dermatology.

Differentiator

Problem solved

Functional benefit

Products and services

  • India Formulations (Domestic Branded Specialty) Domestic Indian market sales of branded specialty pharmaceutical products across multiple therapy areas, distributing through the company's India business sales infrastructure. Targeted at medical professionals, hospitals, and patients in India.
  • International Generics (US ANDA + Global Exports) Global suite of USFDA ANDA-approved generic pharmaceutical products (244+ cumulative approvals) sold through the US front-end and via strategic distribution partnerships across Europe, Canada, Australia, Brazil, and South Africa. Targeted at wholesalers, distributors, pharmacy chains, and healthcare institutions in 75+ countries.
  • Active Pharmaceutical Ingredients (APIs) In-house manufactured pharmaceutical ingredients sold to other pharmaceutical companies globally across therapeutic categories including oncology, cardiovascular, diabetes, and antibiotics, supported by 132 Drug Master File filings.
  • Pivya (pivmecillinam) Tablets Branded antibiotic for uncomplicated urinary tract infections (uUTI) in women; first antibiotic in approximately 20 years to receive FDA approval for uUTI. Marketed through Alembic Therapeutics LLC in approximately 30 US territories.
  • Levothyroxine Sodium Tablets Generic thyroid hormone replacement therapy for hypothyroidism and thyroid cancer management; available in 12 strength variants from 25 mcg to 300 mcg.
  • Dapagliflozin Tablets SGLT2 inhibitor for controlling blood sugar in adults with type-2 diabetes and reducing hospitalization risk for heart failure; available in 5 mg and 10 mg strengths.
  • Oseltamivir Phosphate for Oral Suspension Neuraminidase inhibitor oral suspension used to treat acute, uncomplicated influenza A and B in patients aged two weeks and above.
  • Fingolimod Capsules, 0.5 mg Sphingosine 1-phosphate receptor modulator indicated for treating relapsing forms of multiple sclerosis in patients 10 years and older.
  • Binimetinib Tablets, 45 mg Kinase inhibitor used in combination with encorafenib for treating unresectable or metastatic melanoma with BRAF mutations and metastatic non-small cell lung cancer.
  • Darolutamide Tablets, 300 mg Oral androgen receptor inhibitor for treating non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and in combination with docetaxel.
  • Tretinoin Cream USP, 0.05% Topical cream indicated for the treatment of acne vulgaris.
  • Dapsone Gel, 5% Topical treatment for acne vulgaris.
  • Haloperidol Tablets Antipsychotic medication for managing manifestations of psychotic disorders and controlling tics and vocal utterances of Tourette's Disorder; available in five strengths.
  • Larotrectinib Capsules Kinase inhibitor for treating solid tumors with NTRK gene fusion; available in 25 mg and 100 mg dosages.
  • Methotrexate Injection USP Injection indicated for neoplastic diseases including leukemia and various cancers, rheumatoid arthritis, and severe psoriasis; available in multi-dose and single-dose vial formulations.
  • Lamotrigine Orally Disintegrating Tablets Anticonvulsant for adjunctive therapy in partial-onset seizures, generalized seizures of Lennox Gastaut syndrome, and maintenance treatment of bipolar I disorder.
  • Efinaconazole Topical Solution, 10% Topical antifungal solution for treating onychomycosis of the toenails.
  • Carbidopa, Levodopa and Entacapone Tablets Combination medication for the treatment of Parkinson's disease; available in six dosage strengths.
  • Dasatinib Tablets Generic kinase inhibitor for treating Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).
  • Sumatriptan Injection USP Autoinjector Drug-device combination product for migraine and cluster headache treatment; available in 4 mg/0.5 ml and 6 mg/0.5 ml single-dose autoinjector systems.
  • Dexlansoprazole Delayed-Release Capsules Generic proton pump inhibitor for treating gastroesophageal reflux disease (GERD).
  • Cyclophosphamide Capsules Indicated for treatment of malignant diseases and minimal change nephrotic syndrome in pediatric patients; available in 25 mg and 50 mg dosages.
  • Bosutinib Tablets, 400 mg Kinase inhibitor used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML).
  • Macitentan Tablets, 10 mg Endothelin receptor antagonist for treating pulmonary arterial hypertension.

Quantifiable outcome

  • 11% YoY growth in US formulations business
  • +2 more outcomes

Companies that use Alembic Pharmaceuticals

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Alembic Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Alembic Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Canadian Joint VenturecoreStrategic or Co-development Partner · 6 June 2026Alembic Pharmaceuticals announced acquiring a 45% stake in a Canadian joint venture as part of its strategy to strengthen its global pharmaceutical footprint.
  • Alembic Lifesciences Philippines Inc.minorStrategic or Co-development Partner · 23 April 2026New subsidiary incorporated in the Philippines with parent company holding 99.99% stake. Authorized share capital of 12 million Philippine pesos. Will focus on exploring business opportunities and distributing pharmaceutical products in the region.
  • Enthral.aicoreTechnology or Integration · 1 April 2026Strategic partnership to deploy an AI-powered learning and skilling platform for 9,000+ employees across different regions. The platform addresses compliance, GMP, pharmacovigilance, and regulatory documentation needs specific to regulated pharmaceutical environments, marking Alembic's transition from previous Success Factor LMS system.
  • Utility TherapeuticscoreStrategic or Co-development Partner · 3 July 2024Alembic acquired Utility Therapeutics for approximately $12 million in 2024-25, gaining exclusive commercial rights to Pivya (pivmecillinam) antibiotic for the US market. Pivya was the first antibiotic in about 20 years to gain FDA approval for uncomplicated urinary tract infections.

Scale indicators20 records

Recent moves8 records

Expansion highlights7 records

Alembic Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Sun Pharmaceutical Industries: India's largest pharmaceutical company and the most direct comparator to Alembic, with a similarly diversified US generics business, large India branded formulations franchise, and vertically integrated API manufacturing. Both companies target the same USFDA approval pipeline and compete head-to-head on ANDA molecules.
  • Cipla: Major Indian generic and branded pharmaceutical manufacturer with a strong US generics presence, India branded business, and API capabilities. Directly comparable to Alembic in scale, geographic mix, and therapeutic area focus.
  • Dr. Reddy's Laboratories: Vertically integrated Indian pharmaceutical company with global generics, biosimilars, and API operations. Comparable to Alembic in business model, US generics focus, and integrated API-to-finished-dose manufacturing footprint.
  • Aurobindo Pharma: One of India's largest generic manufacturers with a substantial US generics franchise built on ANDA approvals. Competes directly with Alembic for USFDA approvals on complex molecules including injectables and oncology.
  • Lupin Pharmaceuticals: Indian pharmaceutical company with a leading US generics business, strong pipeline of complex generics, and India branded formulations. Directly comparable to Alembic in regulatory execution and therapeutic coverage.
  • Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical major with a sizable US generics business, India formulations, and API manufacturing. Comparable to Alembic in business mix and pursuit of complex generics and biosimilars.
  • Glenmark Pharmaceuticals: India-headquartered pharma company with US generics, India branded, and API businesses, pursuing complex generics and specialty therapeutics. Closely comparable to Alembic in scale and strategic positioning.
  • Torrent Pharmaceuticals: Indian pharmaceutical company with US generics, India branded formulations, and API manufacturing. Comparable to Alembic in size, vertical integration, and therapeutic mix including cardiovascular and CNS focus.

Broad incumbents

  • Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a dominant US generics portfolio, broad specialty franchise, and global API operations. While much larger and more diversified, Teva sets the competitive benchmark Alembic faces on every major ANDA molecule.
  • Sandoz (Novartis): Global generics leader spun out of Novartis with a leading US generics franchise and broad European presence. Operates as a broad incumbent that competes with Alembic across multiple therapeutic areas and geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Alembic Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alembic Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Alembic Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Alembic Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alembic Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alembic Pharmaceuticals

What does Alembic Pharmaceuticals do?

Alembic Pharmaceuticals manufactures and sells generic pharmaceutical products across therapeutic areas including oncology, cardiovascular, central nervous system, anti-infective, dermatology, diabetes, and gastrointestinal, through three business segments: India Formulations (domestic specialty branded drugs), International Generics (US ANDA-approved generic finished dosage forms and global exports), and Active Pharmaceutical Ingredients (in-house API manufacturing sold to other pharma companies). The company also markets branded specialty drugs in the US through its Alembic Therapeutics LLC subsidiary, with Pivya (pivmecillinam) for uncomplicated urinary tract infections being its first branded product.

Is Alembic Pharmaceuticals a public or private company?

Alembic Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Alembic Pharmaceuticals founded?

Alembic Pharmaceuticals was founded in 1907. It employs 10,001+ people.

Where is Alembic Pharmaceuticals based?

Alembic Pharmaceuticals is headquartered in Vadodara, India, in the Asia region.

How does Alembic Pharmaceuticals make money?

Four revenue lines are on record. US Generics Business are the primary driver. The others are india Formulations, active Pharmaceutical Ingredients (APIs) and US Branded Specialty.

Who are Alembic Pharmaceuticals's main competitors?

Direct peers on record are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma, Lupin Pharmaceuticals, Zydus Lifesciences (Cadila Healthcare), Glenmark Pharmaceuticals and Torrent Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis).

Does Alembic Pharmaceuticals have an API?

No public API is recorded for Alembic Pharmaceuticals.

What industry is Alembic Pharmaceuticals in?

Alembic Pharmaceuticals's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaAlembic Pharma receives USFDA approval for lung cancer drugAlembic Pharmaceuticals received final US FDA approval for its Binimetinib tablets for lung cancer treatment, therapeutically equivalent to Array BioPharma's Mektovi. The company will receive 180 days of generic drug exclusivity for both 15 mg and 45 mg dosages. The drug has an estimated market size of USD 282 million for the 12 months ending September 2026.Business StandardAlembic Pharma receives USFDA approval for lung cancer drug BinimetinibAlembic Pharmaceuticals received final USFDA approval for its Abbreviated New Drug Application for Binimetinib tablets for lung cancer. The company is eligible for 180 days of generic exclusivity, and IQVIA estimates a $282 million market size for the 12 months ending September 2026.TradingViewCulture Evolves When People Act Without Reminders: Alembic CHRO On Lasting ChangeNamita Patwari, CHRO of Alembic Pharmaceuticals, discusses how lasting cultural change requires employee involvement and visible leadership, with the real test being behavior when no reminders are given. She highlights AI-enabled learning via RepReadyAI and integrating wellbeing into daily work, and advises early listening and leadership alignment for successful mergers.ScanXAlembic Pharmaceuticals secures USFDA approval for Venetoclax tabletsAlembic Pharmaceuticals received USFDA final approval for Venetoclax tablets (10, 50, 100 mg) on October 30, 2026, therapeutically equivalent to AbbVie's Venclexta. The product targets CLL and AML patients, with a US market estimated at $1,584 million for the year ending June 2026. As a first ANDA applicant with paragraph IV certification, Alembic may be eligible for 180 days of generic drug exclusivity.Drug Store NewsAlembic rolls out Tretinoin Cream 0.05%Alembic Pharmaceuticals has launched its generic Tretinoin Cream 0.05% in the United States, establishing bioequivalence and therapeutic equivalence to Valeant International Bermuda's Retin-A. The product is indicated for acne vulgaris treatment and is available in 20 gm and 45 gm tubes. This release marks Alembic USA’s 181st product launch since it began U.S. operations in October 2015.DrugPatentWatchAmneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd.The article discusses a federal patent dispute filed in 2026 between Amneal Pharmaceuticals LLC and Alembic Pharmaceuticals Ltd., involving a challenge to generic drug approval under the Hatch-Waxman Act. No specific details about the patents or claims involved are provided in the input. The case is a standard patent litigation track without further elaboration.Business News TodayAlembic Pharma raises FY27 US growth outlook after strong Q1, bets on exclusivity gains and India turnaroundAlembic Pharma has raised its FY27 growth outlook for the US market following a strong first quarter performance. The company is leveraging the upcoming loss of exclusivity for Bosutinib, which will provide a full quarter of sales benefits in September, while simultaneously focusing on a turnaround strategy in India.PrtimesThe Amdinocillin Market: A Promising Future for Antibiotic Therapy – PR TimesThe global Amdinocillin market is projected to grow from US$1.28 billion in 2025 to US$2.78 billion by 2034, representing a compound annual growth rate of 8.98%, driven by increasing resistance to standard urinary anti-infectives and expanding antimicrobial stewardship programs. The urinary tract infections segment dominates the market with a 62–66% share in 2025, while the Asia Pacific region shows the highest growth rate at 9.4–10.1% CAGR despite holding only 20–24% of market share. Key pharmaceutical companies including Novartis AG, Pfizer Inc., Eisai Co., Utility Therapeutics Ltd., and Alembic Pharmaceuticals Limited are identified as pivotal players shaping the market landscape.YahooAlembic Pharmaceuticals Ltd (BOM:533573) (Q1 2027) Earnings Call Highlights: Strong Revenue ...Alembic Pharmaceuticals reported strong Q1 FY27 earnings with consolidated revenue growing 26% year-on-year, driven by broad-based growth across all major business segments including US generics (49% YoY), international generics (37% YoY), and API (33% YoY). The company raised its FY27 growth outlook for US generics to mid-to-high teens and overall company growth to mid-teens, reflecting strong momentum and execution. Key headwinds include pricing pressure in the US generics market, margin dilution from the US branded specialty soft launch, and rising solvent prices impacting gross margins.Investing.comEarnings call transcript: Alembic Pharmaceuticals lifts FY 2027 growth outlook By Investing.comAlembic Pharmaceuticals reported Q1 FY2027 revenue of INR 2,150 crore, up 26% year-on-year, driven by strong growth across U.S. generics (49%), international generics (37%), and API business (33%), while India branded medicines grew 7%. The company raised its FY2027 full-year revenue growth outlook to mid-teen range from low double digits, citing stronger-than-expected U.S. generics momentum and an active launch pipeline (7 product launches, 10 approvals, 4 ANDA filings in the quarter). EBITDA margin remained stable at 16% as investments in R&D (INR 186 crore, ~9% of revenue) and the new U.S. branded specialty platform offset operational leverage, with management expecting the branded business to approach breakeven by end of FY2027.